LY3202626
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
2
Sites
122
Countries
4
Endpoints
48
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 48 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 18 of 48 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
6
4
2
2
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NAVIGATE-ADA Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia | LY3202626 Alzheimer’s disease | mild AD dementia | Ph 2 | Terminated | 76 | Jul 2018 | - | results |
| NCT03367403A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) | Donanemab, LY3202626 Alzheimer’s disease | MMSE 20-28 | Ph 2 | Completed | 61 | Dec 2020 | 8 | results |
| NCT02323334A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease | LY3202626 Alzheimer’s disease | mild-to-moderate AD | Ph 1 | Completed | 1 | Feb 2016 | - | results |
Showing 1-3 of 3 trials